Biblio
“Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.”, J Alzheimers Dis, vol. 61, no. 1, pp. 265-281, 2018.
, “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.
, “Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau.”, J Alzheimers Dis, vol. 53, no. 1, pp. 1-14, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.”, J Alzheimers Dis, vol. 97, no. 2, pp. 635-648, 2024.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “Current Status and Challenges of Stem Cell Treatment for Alzheimer's Disease.”, J Alzheimers Dis, vol. 84, no. 3, pp. 917-935, 2021.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.”, J Alzheimers Dis, vol. 50, no. 1, pp. 101-10, 2016.
, “Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau.”, J Alzheimers Dis, vol. 62, no. 2, pp. 737-744, 2018.
, “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 195-208, 2018.
, “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
, “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
, “Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.”, J Alzheimers Dis, vol. 52, no. 2, pp. 433-49, 2016.
,